Stay updated with breaking news from Late Breaking Science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Allschwil, Switzerland - May 31, 2024 Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan, Idorsia's endothelin receptor antagonist, will be presented by Prof.
A new technology using ultralow temperature cryoablation (ULTC) has eliminated clinical ventricular tachycardia (VT) in 94% of patients. The late-breaking science was presented this week during EHRA 2024, a scientific congress of the European Society of Cardiology (ESC).1 which took place April 7-9 in Berlin, Germany.
<p>The first randomised trial to investigate preventive ablation of a potential arrhythmogenic substrate associated with coronary chronic total occlusion (CTO) in patients at high risk of ventricular arrhythmias (VAs) reduces the risk of appropriate implantable cardioverter-defibrillator (ICD) therapy and unplanned hospitalisation in patients with no previously recorded VAs. The late-breaking science is presented at EHRA 2024, a scientific congress of the European Society of Cardiology (ESC).</p> <p>Principal investigator Dr. David Zizek of the University Medical Ce...
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of...
Full IDE Data Set Demonstrates Statistically Significant Reduction of All-Cause Mortality and Primary Major Adverse Events at 30 days with use of AMDS in Acute DeBakey Type I Dissections...